Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
CK-101 · 1 trial · 4 indications
| Arm | Type | Description |
|---|---|---|
| Daily dose of CK-101 | EXPERIMENTAL | Daily oral dose of CK-101 |
| Name | Type | Description |
|---|---|---|
| CK-101 | DRUG | Phase 1: CK-101 will be administered in escalating dosages in a period of 21-day cycles Phase 2: CK-101 will be administered daily |
Inclusion Criteria: * Measureable disease according to RECIST Version 1.1 * Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 * Minimum age of 18 years * Adequate hematological, hepatic and renal function * Written consent on an Institutional Review Board-approved informed cons...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Bristol-Myers Squibb Company | BMY | 5 | PHASE3 | ACE-536 |
| AbbVie, Inc. | ABBV | 4 | PHASE3 | Navitoclax, Ruxolitinib |
| Novartis AG Sponsored ADR | NVS | 3 | PHASE3 | Pelabresib, Ruxolitinib |
| Karyopharm Therapeutics, Inc. | KPTI | 4 | PHASE3 | Selinexor, Ruxolitinib |
| Geron Corporation | GERN | 2 | PHASE3 | Imetelstat |
| Merck & Co., Inc. | MRK | 1 | PHASE3 | Bomedemstat |
| Incyte Corporation | INCY | 10 | PHASE2 | Ruxolitinib |
| GSK plc Sponsored ADR | GSK | 2 | PHASE2 | MMB |
| Takeda Pharmaceutical Co. Ltd. Sponsored ADR | TAK | 1 | PHASE2 | Elritercept, Ruxolitinib |
| Eli Lilly and Company | LLY | 1 | PHASE1 | LY3410738, Venetoclax, Azacitidine |
| Disc Medicine, Inc. | IRON | 1 | PHASE1 | DISC-0974 |
| Galecto, Inc. | GLTO | 1 | PHASE2 | GB2064 |
| Prelude Therapeutics, Inc. | PRLD | 1 | PHASE1 | PRT12396 |
| United Therapeutics Corporation | UTHR | 1 | PHASE2 | bomedemstat |
CK-101 is an investigational small molecule being studied for the treatment of lung neoplasms, including non-small-cell lung cancer and adenocarcinoma. It is in Phase 1 clinical development for these oncology indications.
The molecular target of CK-101 has not been disclosed. It is a small molecule in development for lung neoplasms, but its specific mechanism of action is not publicly specified in available clinical trial information.
CK-101 is being developed by Fortress Biotech, Inc., a biopharmaceutical company traded on NASDAQ under the ticker symbol FBIO.
CK-101 is in Phase 1 clinical development. A Phase I/II study has been completed, but the drug remains investigational and has not been approved by regulatory authorities.
CK-101 has been studied in one completed clinical trial, NCT02926768, a Phase I/II study in patients with non-small-cell lung cancer and other advanced solid tumors. The trial enrolled 136 participants across the United States, Australia, New Zealand, Poland, and Thailand.